Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

OPKO HEALTH, INC.
Next earnings Jul 29, 2026 · consensus $-0.08 EPS, $132M rev
Last earnings +0.8% on 2026-04-28
Conservative balance sheet (liabilities/equity 0.52x); but revenue fell -14.9% YoY.
OPKO HEALTH, INC. shows $607M in FY2025 revenue (-14.9% YoY), a -37.2% net margin, and -17.8% ROE.
Sources: SEC EDGAR (CIK 0000944809, latest 10-Q filed 2026-04-28) · EODHD · as of 6/22/2026, 12:30:29 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.77B | $1.00B | $863M | $713M | $607M |
| Gross profit | — | $288M | $318M | $219M | $206M |
| Operating income | $18.8M | -$226M | -$157M | -$152M | -$117M |
| Net income | -$30.1M | -$328M | -$189M | -$53.2M | -$226M |
| Diluted EPS | -$0.05 | -$0.46 | -$0.25 | -$0.08 | -$0.30 |
| Net margin | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
| 2026-03-20 | PAGANELLI JOHN A Director | Buy | 10.0K @ $1.14 | $11.3K |
| 2025-11-21 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 102K @ $1.30 | $133K |
| 2025-11-21 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 3.89K @ $1.32 | $5.14K |
| 2025-11-21 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 89.4K @ $1.33 | $118K |
| 2025-11-21 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 191K @ $1.33 | $255K |
| 2025-11-21 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 193K @ $1.34 | $257K |
| 2025-11-20 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 119K @ $1.32 | $157K |
| 2025-11-20 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 47.1K @ $1.33 | $62.4K |
| 2025-11-20 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 212K @ $1.33 | $282K |
| 2025-11-20 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 162K @ $1.34 | $216K |
| 2025-11-20 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 24.6K @ $1.34 | $32.9K |
| 2025-11-20 | FROST PHILLIP MD ET AL CEO & Chairman | Buy | 1.76K @ $1.35 | $2.36K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.